Rights Issue

July 31, 2026 BSE Limited National Stock Exchange of India Ltd. Corporate Relationship Department Exchange Plaza, Bandra- P.J. Towers, Kurla Complex, Bandra Dalal Street, Fort, (East) Mumbai - 400 051 Mumbai - 400 001 Scrip Code : 506109 Symbol : GENESYS Dear Sir/Madam, Sub: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”) and outcome of the meeting of the Rights Issue Committee of the Board of Directors of Genesys International Corporation Limited (the “Company”) held on July 31, 2026. Ref: Regulation 30 of the SEBI Listing Regulations This is further to the meeting of the Board of Directors of our Company (the “Board”) held on June 26, 2026, approving the issue of equity shares of the Company by way of Rights Issue to the eligible Shareholders of the Company as on the record date i.e., Thursday, August 06, 2026 (such issue, the “Rights Issue”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Pursuant to the above and the in-principle approvals received from BSE Limited and National Stock Exchange of India Limited vide their letters each dated July 27, 2026, for the Rights Issue, we wish to inform you that Rights Issue Committee constituted by the Board of Directors of the Company for the Rights Issue (the “Rights Issue Committee”), inter alia, considered and approved the following terms of the Rights Issue at its meeting held today, i.e. on July 31, 2026: 1. Instrument: Fully paid-up Rights Equity Shares of the Company of face value of ₹ 5 each. 2. Total Number of Equity Shares and Issue Size: 2,50,74,226 fully paid-up Equity Shares of face value of ₹ 5 each, for an aggregate amount not exceeding ₹ 12,537.11 lakhs. 3. Rights Issue Price: ₹ 50 each per Rights Equity Share [including, a premium of ₹ 45 per Rights Equity Share]. 4. Record Date: Thursday, August 06, 2026, to determine the existing equity shareholders who will be eligible to participate in the Rights Issue and receive the rights entitlement (the “Eligible Equity Shareholders”). Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com CIN: L65990MH1983PLC029197 5. Rights Entitlement Ratio: 3 (three) rights Equity Shares for every 5 (five) fully paid-up Equity Shares held by the eligible equity shareholders of the Company, as on the Record Date. 6. Rights Issue Opening Date: Friday, August 14, 2026 7. On-market Renunciation Period (Start): Friday, August 14, 2026 8. On-market Renunciation Period (End): Tuesday, August 18, 2026 9. Rights Issue Closing Date*: Friday, August 21, 2026 *The Board of Directors and/ or Rights Issue Committee have the right to extend the Issue closing date, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). 10. ISIN for Credit of Dematerialized Rights Entitlement: INE727B20018 11. Rights Entitlement ratio and Treatment of fractional Entitlement: (a) Equity Shares are being offered on a rights basis to eligible equity shareholders in the ratio of 3 (three) Equity Shares for every 5 (five) Equity Shares held on the Record Date. For Equity Shares being offered on a rights basis under this Issue, if the shareholding of any of the Eligible Equity Shareholders is less than 5 (five) Equity Shares or not in the multiple of 5 (five), the fractional entitlement of such Eligible Equity Shareholders shall be ignored in the computation of the Rights Entitlement. However, the Eligible Equity Shareholders whose fractional entitlements are being ignored, will be given preferential consideration for the allotment of one additional Equity Share each if they apply for additional Equity Shares over and above their Rights Entitlement, if any, subject to availability of Equity Shares in the Issue post allotment towards rights entitlement applied for. (b) Further, the Eligible Equity Shareholders holding less than 5 (five) Equity Shares as on Record Date shall have ‘zero’ entitlement in the Rights Issue. Such Eligible Equity Shareholders are entitled to apply for additional Equity Shares and will be given preference in the allotment of one additional Equity Share if, such Eligible Equity Shareholders apply for additional Equity Shares. However, they cannot renounce the same in favour of third parties and the application forms shall be non-negotiable. 12. Outstanding Equity Shares: (a) Prior to the Rights Issue: 4,17,90,377 fully paid-up equity shares of face value of ₹5 each. Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com CIN: L65990MH1983PLC029197 (b) Post the Rights Issue#: 6,68,64,603 fully paid-up equity shares of face value of ₹ 5 each. #Assuming full subscription 13. Dividend: Such dividend, as may be recommended by our Board and declared by the shareholders, in accordance with applicable law. 14. Rights Equity Shares in Abeyance: The Rights Entitlement on the Equity Shares, the ownership of which is currently under dispute and including any court proceedings or are currently under transmission or are held in a demat suspense account and for which the Company has withheld the dividend, shall be held in abeyance and the application form along with the Rights Entitlement letter in relation to these Rights Entitlements shall not be dispatched pending resolution of the dispute or court proceedings or completion of the transmission or pending their release from the demat suspense account. On submission of such documents / records confirming the legal and beneficial ownership of the Equity Shares with regards to these cases on or prior to the closing date of the Issue, to the satisfaction of the Company, the Company shall make available the Rights Entitlement on such Equity Shares to the identified Eligible Equity Shareholder. 15. All other terms and conditions of the Rights Issue (including fractional entitlement and zero entitlement) as included in the Letter of Offer. We further wish to inform you that, at its meeting held today, i.e., July 31, 2026, the Rights Issue Committee also considered other modalities relating to the Rights Issue. The meeting of the Rights Issue Committee commenced at 3.00 p.m. and concluded at 5.10 p.m. We request you to take the above on record and disseminate the same on your website. Yours faithfully, for Genesys International Corporation Limited Kushal Jain Company Secretary & Compliance Officer Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com CIN: L65990MH1983PLC029197